ATTENUATED RECOMBINANT NEWCASTLE DISEASE VIRUS AND VACCINE CONTAINING THE SAME
원문보기
IPC분류정보
국가/구분
United States(US) Patent
공개
국제특허분류(IPC7판)
A61K-039/17
A61P-031/14
C12N-007/00
출원번호
US-0442749
(2006-09-27)
공개번호
US-0183664
(2010-07-22)
우선권정보
KR-10-2006-0093620(2006-09-26)
국제출원번호
PCT/KR2006/003837
(2006-09-27)
발명자
/ 주소
Cho, Sun-Hee
Kwon, Hyuk-Joon
Kim, Sun-Joong
Kim, Tae-Eun
An, Young-Jin
Ko, Mi-Joung
Kim, Il-Hwan
Park, Young-Ho
Kim, Chae-Hyun
Han, Jang-Hyuck
Kim, Tae-Hwan
출원인 / 주소
KBNP, Inc.
대리인 / 주소
LEXYOUME IP GROUP, LLC
인용정보
피인용 횟수 :
0인용 특허 :
0
초록▼
The present invention relates to a recombinant vector for transcription of the Newcastle disease virus (NDV) genome, a strain of attenuated recombinant NDV with a surface antigen of pathogenic NDV prepared by the vector, a method of preparing a recombinant NDV having low pathogenicity and high prote
The present invention relates to a recombinant vector for transcription of the Newcastle disease virus (NDV) genome, a strain of attenuated recombinant NDV with a surface antigen of pathogenic NDV prepared by the vector, a method of preparing a recombinant NDV having low pathogenicity and high protectivity efficiency against Newcastle disease (ND) using the vector, and a vaccine against ND containing the recombinant NDV.
대표청구항▼
1.-20. (canceled) 21. A strain of Newcastle disease virus, comprising nucleotide sequences encoding NP, P, M, and L proteins of a low-pathogenic Newcastle disease virus that has an amino acid sequence represented by following Formula 1 at 113th to 116th positions of F protein; and nucleotide sequ
1.-20. (canceled) 21. A strain of Newcastle disease virus, comprising nucleotide sequences encoding NP, P, M, and L proteins of a low-pathogenic Newcastle disease virus that has an amino acid sequence represented by following Formula 1 at 113th to 116th positions of F protein; and nucleotide sequences encoding F, and HN proteins of a high-pathogenic Newcastle disease virus that has an amino acid sequence represented by following Formula 2 at 113th to 116th positions of the F protein, wherein the F protein coding sequence comprised in the strain is characterized by substitution of the codon encoding the 115th amino acid of the F protein of the high-pathogenic Newcastle disease virus with any one selected from the group consisting of alanine codons consisting of GCA, GCC, GCG and GCU; aspartic acid codons consisting of GAC and GAU; phenylalanine codons consisting of UUC and UUU; isoleucine codons consisting of AUC and AUU; leucine codons consisting of UUA and UUG; serine codons consisting of UCA, UCC, UCG and UCU; threonine codons consisting of ACC and ACU; valine codons consisting of GUA, GUC, GUG and GUU; and tyrosine codons consisting of UAC and UAU: 113-X1X2X3X4-116 Formula 1 wherein X1, X3 and X4 are independently arginine (R) or lysine (K), and X2 is selected from the group consisting of alanine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan, valine, asparagine, cysteine, glutamine, glycine, serine, theronine, tyrosine, aspartic acid, glutamic acid, arginine, histidine, and lysine. 113-X4X5X7X8-116 Formula 2 wherein X5, X6 and X7 are independently selected from the group consisting of alanine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan, valine, asparagine, cysteine, glutamine, glycine, serine, theronine, tyrosine, aspartic acid, glutamic acid, arginine, histidine and lysine, and X5 and X7 are not both arginine (R) or lysine (K) at the same time, and X8 is arginine (R) or lysine (K). 22. The strain according to claim 21, wherein the low-pathogenic Newcastle disease virus is selected from the group consisting of genotype II Newcastle disease viruses, and the high-pathogenic Newcastle disease virus is selected from the group consisting of genotype VI and VII Newcastle disease viruses. 23. The strain according to claim 22, wherein the low-pathogenic Newcastle disease virus is La Sota/46 strain (AY845400), and the high-pathogenic Newcastle disease virus is KBNP-C4152 (KCTC 10919BP). 24. The strain according to claim 21, wherein the nucleotide sequence encoding the HN protein is a nucleotide sequence encoding a recombinant HN protein wherein the amino acid sequence after the 570th position of the HN protein of the low-pathogenic Newcastle disease virus is linked to the C-terminus of the 569th residue of the HN protein of the high-pathogenic Newcastle disease virus. 25. The strain according to claim 21, wherein the strain is KCTC 10984BP. 26. A vaccine against Newcastle disease containing the stain of Newcastle disease virus of claim 21, wherein the strain comprises nucleotide sequences encoding NP, P, M, and L proteins of a low-pathogenic Newcastle disease virus that has an amino acid sequence represented by following Formula 1 at 113th to 116th positions of an F protein; and nucleotide sequences encoding F, and HN proteins of a high-pathogenic Newcastle disease virus that has an amino acid sequence represented by following Formula 2 at 113th to 116′ positions of the F protein, and the F protein coding sequence comprised, in the strain is characterized by substitution of the codon encoding the 115th amino acid of the F protein of the high-pathogenic Newcastle disease virus with any one selected from the group consisting of alanine codons consisting of GCA, GCC, GCG and GCU; aspartic acid codons consisting of GAC and GAU; phenylalanine codons consisting of UUC and UUU; isoleucine codons consisting of AUC and AUU; leucine codons consisting of UUA and UUG; serine codons consisting of UCA, UCC, UCG and UCU; threonine codons consisting of ACC and ACU; valine codons consisting of GUA, GUC, GUG and GUU; and tyrosine codons consisting of UAC and UAU: 113-X1X2X3X4-116 Formula 1 wherein X1, X3 and X4 are independently arginine (R) or lysine (K), and X2 is selected from the group consisting of alanine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan, valine, asparagine, cysteine, glutamine, glycine, serine, theronine, tyrosine, aspartic acid, glutamic acid, arginine, histidine, and lysine. 113-X4X5X7X8-116 Formula 2 wherein X5, X6 and X7 are independently selected from the group consisting of alanine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan, valine, asparagine, cysteine, glutamine, glycine, serine, theronine, tyrosine, aspartic acid, glutamic acid, arginine, histidine and lysine, and X5 and X7 are not both arginine (R) or lysine (K) at the same time, and X8 is arginine (R) or lysine (K). 27. The vaccine according to claim 26, wherein the low-pathogenic Newcastle disease virus is selected from the group consisting of genotype II Newcastle disease viruses, and the high-pathogenic Newcastle disease virus is selected from the group consisting of genotype VI and VII Newcastle disease viruses. 28. The vaccine according to claim 27, wherein the low-pathogenic Newcastle disease virus is La Sota/46 strain (AY845400), and the high-pathogenic Newcastle disease virus is KBNP-C4152 (KCTC 10919BP). 29. The vaccine according to claim 26, wherein the nucleotide sequence encoding the HN protein is a nucleotide sequence encoding a recombinant HN protein wherein the amino acid sequence after the 570th position of the HN protein of the low-pathogenic Newcastle disease virus is linked to the C-terminus of the 569th residue of the HN protein of the high-pathogenic Newcastle disease virus. 30. The vaccine according to claim 26, wherein the strain is KCTC 10984BP. 31. The vaccine according to claim 26, wherein the vaccine is used as a type of one selected from the group consisting of an inactivated killed vaccine, a live vaccine, and an in ovo vaccine. 32. The vaccine according to claim 27, wherein the vaccine is used as a type of one selected from the group consisting of an inactivated killed vaccine, a live vaccine, and an in ovo vaccine. 33. The vaccine according to claim 28, wherein the vaccine is used as a type of one selected from the group consisting of an inactivated killed vaccine, a live vaccine, and an in ovo vaccine. 34. The vaccine according to claim 29, wherein the vaccine is used as a type of one selected from the group consisting of an inactivated killed vaccine, a live vaccine, and an in ovo vaccine. 35. The vaccine according to claim 30, wherein the vaccine is used as a type of one selected from the group consisting of an inactivated killed vaccine, a live vaccine, and an in ovo vaccine.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.